Glenmark Pharma gets DCGI nod for clinical trials of Favipiravir tablets on COVID-19 patients
Glenmark Pharmaceuticals on Thursday said it has become the first
company in India to receive approval from Drug Controller General of
India (DCGI) to conduct clinical trials of Favipiravir antiviral
tablets for the treatment of COVID-19 patients.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-pharma-gets-dcgi-nod-for-clinical-trials-of-favipiravir-tablets-on-covid-19-patients/articleshow/75465661.cms
company in India to receive approval from Drug Controller General of
India (DCGI) to conduct clinical trials of Favipiravir antiviral
tablets for the treatment of COVID-19 patients.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-pharma-gets-dcgi-nod-for-clinical-trials-of-favipiravir-tablets-on-covid-19-patients/articleshow/75465661.cms
Comments
Post a Comment